OmniComm Systems, Inc. Delivers Its Study Data Tabulation Model (SDTM) Export Tool Ahead of Its Planned 2010 Release Date

FORT LAUDERDALE, FL--(Marketwire - October 15, 2009) -

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the electronic data capture (EDC) marketplace, announced today that its new SDTM solution is ready, ahead of schedule, and is available to its customers for deployment and implementation into clinical studies. This new solution was developed for OmniComm’s flagship EDC product, TrialMaster™ and will allow for mapping and exporting of data directly into the CDISC SDTM format, ensuring an accelerated pathway towards electronic submission of clinical data. OmniComm is a CDISC ODM certified partner and is known in the industry for its commitment to standards and for bringing innovative eClinical solution to the life science industry. OmniComm’s TrialMaster solution has supported the CDISC ODM, CDASH (including naming conventions and domain structures), HL7, E2B, and caBIG standards for years, and with the addition of CDISC SDTM, will be the first EDC company to leverage all of the industry leading standards in a single solution.

“TrialMaster™ offers an end-to-end solution from designing electronic case report forms (eCRFs) that support the CDASH naming conventions, to supporting the export of the CDISC submission format (SDTM), the preferred method for submission by the Food and Drug Administration,” commented Stephen Johnson, OmniComm’s COO. “Our focus is on how to aggregate, extract and export the data into industry standards while reducing the time between database lock and reporting to FDA. OmniComm has always been on the forefront of adopting new technologies. For example, we are currently working with one of our customers at a premier research institute to integrate our TrialMaster application with their Electronic Health Records (EHR) system to integrate healthcare and clinical research data. We are constantly searching for better ways to improve clinical research through the use of innovative technologies.”

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company’s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.